Clinical trial saves man initially given weeks to live: "Not done yet"
Summary
Ryan Goepel, diagnosed with a serious form of blood cancer called acute myeloid leukemia (AML), was told he had only weeks to live. He joined a clinical trial testing new medication combinations, and within just a few weeks, his cancer went into remission.Key Facts
- Ryan Goepel was diagnosed with AML, a blood cancer with about a 30% five-year survival rate.
- His AML was classified as adverse-risk, meaning usual chemotherapy would likely be ineffective or harmful.
- Doctors advised hospice care because his condition was severe and organs were failing.
- Goepel joined a clinical trial testing two medications for younger patients with older-patient-like AML genetics.
- Treatment started immediately with a daily pill for 28 days and an infusion during the first week.
- Within two weeks of treatment, Goepel’s cancer significantly improved, and he entered remission.
- The trial showed that 25 out of 36 patients had their cancer shrink or disappear after 28 days.
- Standard treatment effectiveness is about 44% for similar adverse-risk patients, meaning this trial’s results are promising.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
